Author + information
- K. Sivaprasad1,
- Jaspal Singh Arneja2,
- Dilip Kumar3,
- Parneesh Arora4,
- Madanmohan Balakrishnan5,
- T.R. Raghu6,
- Deepak Davidson7,
- Sanjeeb Roy8 and
- Subhash Chandra9
- 1Govt T.D Medical College, Vandanam, Kerala, India
- 2Arneja Heart & Multispeciality Hospital, Nagpur, Maharashtra, India
- 3Medica Superspecialty Hospital, Kolkata, West Bengal, India
- 4Fortis Hospital, Noida, Uttar Pradesh, India
- 5Fortis Malar Hospital, Chennai, Tamil Nadu, India
- 6Sri Jayadeva Institute of Cardiovascular Science and Research, Banglore, Karnataka, India
- 7Caritas hospital, Kottayam, Kerala, India
- 8Fortis Escorts Hospital, Jaipur, Rajasthan, India
- 9BLK Super Speciality Hospital, New Delhi, Delhi, India
Early-generation stents had stainless-steel platforms and released sirolimus or paclitaxel, while new-generation stents release everolimus and feature cobalt-chromium with an ultrathin strut (50 μm). The aim of the study was to determine the safety and performance of ultrathin strut biodegradable polymer-coated with everolimus-eluting coronary stent (EES, Evermine 50™, Meril Life Sciences, India) in patients with coronary artery disease (CAD).
This was a prospective, non-randomised, multi-center study conducted in 110 patients who had undergone EES implantation for the treatment of CAD at nine clinical sites in India. Study end-points were major adverse cardiac events (MACE), defined as a composite of cardiac death, myocardial infarction (MI) and ischemia-driven target lesion revascularization at 6-month follow-up.
A total of 110 patients were included with mean patient age was 57.87 ± 11.63 years and 87 (79.1%) were male. Among these, 55 (50%) patients had hypertension and 44 (40%) patients with diabetics. A total of 128 lesions were treated with EES. Single vessel disease was present in 46 (41.8%) patients and most of the lesions were located in the left anterior descending artery 62 (48.4%). Device and procedural success was 100%. At 6-month follow-up, no MACE was observed. No stent thrombosis or MI was reported.
The present study demonstrated the safety and performance of ultra-thin strut everolimus-eluting coronary stent in real-world coronary artery disease patients. CTRI number- CTRI/2017/02/007781
CORONARY: Stents: Drug-Eluting